FindTrial
Sign In

Effect of three different ticagrelor loading dose formulations (crushed, chewed or intact tablets) on the degree and rapidity of platelets ability to clump together and form clots in patients with stable angina referred for coronary angiography

Inhibition of platelet aggregation after administration of three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography - IPAAD-Tica

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2014-002227-96-SE
Enrollment
Unknown
Registered
2014-07-29
Start date
2014-09-17
Completion date
Unknown
Last updated
2016-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effect of three ticagrelor loading dose formulations on the degree and rapidity of platelet aggregation in patients with stable angina referred for coronary angiography

Interventions

Trade Name: Brilique Pharmaceutical Form: Tablet

Sponsors

County Council of Östergötland
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with stable angina referred for coronary angiography Ability to provide informed consent Age 18 years or older Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50

Exclusion criteria

Exclusion criteria: Pregnacy or lactation, chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine, treatment with warfarin or NOAC in the last 4 days, active bleeding or increased risk of bleeding, history of gastrointestinal or geniourinary bleeding in the last 2 months, history of intracranial bleeding, major surgery in the last 4 weeks, severe anaemia or thrombocytopenia, severe liver or renal disease, increased risk of bradycardia, unable to chew tablet.

Design outcomes

Primary

MeasureTime frame
Main Objective: The proportion of patients with high on treatment platelet reactivity 20 and 60 minutes after three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography;Secondary Objective: Residual platelet reactivity 20 and 60 minutes after three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography;Primary end point(s): The proportion of patients with high on treatment platelet reactivity 20 and 60 minutes after three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography;Timepoint(s) of evaluation of this end point: 20 and 60 minutes after three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography—

Secondary

MeasureTime frame
Secondary end point(s): Residual platelet reactivity 20 and 60 minutes after three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography;Timepoint(s) of evaluation of this end point: 20 and 60 minutes after three different ticagrelor loading dose formulations in patients with stable angina referred for coronary angiography—

Countries

Sweden

Contacts

Public ContactDimitrios Ventsanos

County Council of Östergötland

dimitrios.venetsanos@liu.se0046768844561

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026